Now turning to FSGS, FILSPARI continues to be the only potential treatment in development with data showing efficacy across patients with either biopsy proven or genetic FSGS. Importantly ...

In steroid-resistant nephrotic syndrome (SRNS), including focal segmental glomerulosclerosis (FSGS), genetic causes should be excluded at the time of renal biopsy. Pulse methylprednisolone should ...

Focal segmental glomerulosclerosis (FSGS) refers to scarring in scattered ... the person is producing less urine than usual. A kidney biopsy involves using a small needle to take a sample of ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO, May 15, 2025--(BUSINESS WIRE)--Travere ...

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).

Each year, millions of pulmonary nodules are identified incidentally or through lung cancer screening, and many involve biopsy to distinguish cancer from benign processes. Both navigational ...

SAN DIEGO - Travere Therapeutics, Inc. (NASDAQ: TVTX) has reached a significant milestone in the potential treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disease, with the U.S.

has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for treating focal segmental glomerular sclerosis (FSGS). Following a Type C meeting ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...